Stocktoria
Alzamend Neuro, Inc. ALZN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-15
Alzamend Neuro, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $1.4M | $6.5M | $7.4M | $5.2M | $1.3M |
| Operating income | -$4.5M | -$9.9M | -$14.9M | -$12.3M | -$5.0M |
| Interest expense | $18,029 | $10,101 | $7,701 | $46,524 | $142,421 |
| Net income | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M |
| EPS (diluted) | $-11.32 | $-132.33 | $-22.89 | $-0.14 | — |
| Operating cash flow | -$6.6M | -$8.3M | -$8.9M | -$6.6M | -$2.7M |
| Cash & equivalents | $3.9M | $376,048 | $5.1M | $14.1M | $1.9M |
| Total assets | $4.6M | $631,588 | $5.9M | $14.5M | $2.9M |
| Total liabilities | $634,761 | $3.2M | $2.9M | $1.2M | $899,643 |
| Shareholders' equity | $4.0M | -$2.6M | $3.0M | $13.4M | $2.0M |
Source: SEC EDGAR filings · CIK 0001677077 · as of 2025-04-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.